X-linked spastic paraplegia type 34

X-linked spastic paraplegia type 34 (SPG34) is an extremely rare hereditary spastic paraplegia characterized by progressive spasticity and weakness of the lower limbs. This condition is caused by a genetic defect mapped to the Xq24-q25 region, and it follows an X-linked recessive inheritance pattern, meaning it predominantly affects males while females may be carriers. The disease primarily affects the corticospinal tracts of the central nervous system, leading to upper motor neuron dysfunction in the lower extremities. Clinically, SPG34 presents as a relatively pure form of spastic paraplegia. Affected individuals develop progressive spasticity and weakness in the legs, resulting in gait difficulties that worsen over time. Hyperreflexia and extensor plantar responses (Babinski sign) are typical neurological findings. The age of onset has been reported in childhood to adolescence. Upper limb function and cognitive abilities are generally preserved, distinguishing it from more complicated forms of hereditary spastic paraplegia. There is currently no cure or disease-modifying treatment for SPG34. Management is symptomatic and supportive, focusing on physical therapy to maintain mobility, antispasticity medications such as baclofen or tizanidine to reduce muscle stiffness, and orthopedic interventions as needed. Given the extreme rarity of this condition, with only a very limited number of families reported in the medical literature, knowledge about the full clinical spectrum and long-term prognosis remains limited.

Common questions about X-linked spastic paraplegia type 34